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Abstract
Neurodegenerative and psychiatric disorders including Alzheimer’s, Parkinson’s or Huntington’s diseases and schizophrenia
have been associated with a deficit in glutathione (GSH). In particular, a polymorphism in the gene of glutamate cysteine
ligase modulatory subunit (GCLM) is associated with schizophrenia. GSH is the most important intracellular antioxidant and
is necessary for the removal of reactive by-products generated by the utilization of glucose for energy supply. Furthermore,
glucose metabolism through the pentose phosphate pathway is a major source of NADPH, the cofactor necessary for the
regeneration of reduced glutathione. This study aims at investigating glucose metabolism in cultured astrocytes from GCLM
knockout mice, which show decreased GSH levels. No difference in the basal metabolism of glucose was observed between
wild-type and knockout cells. In contrast, glycogen levels were lower and its turnover was higher in knockout astrocytes.
These changes were accompanied by a decrease in the expression of the genes involved in its synthesis and degradation,
including the protein targeting to glycogen. During an oxidative challenge induced by tert-Butylhydroperoxide, wild-type
cells increased their glycogen mobilization and glucose uptake. However, knockout astrocytes were unable to mobilize
glycogen following the same stress and they could increase their glucose utilization only following a major oxidative insult.
Altogether, these results show that glucose metabolism and glycogen utilization are dysregulated in astrocytes showing a
chronic deficit in GSH, suggesting that alterations of a fundamental aspect of brain energy metabolism is caused by GSH
deficit and may therefore be relevant to metabolic dysfunctions observed in schizophrenia.
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Introduction
Cellular respiration is an essential process during which the
energy derived from the oxidation of carbon atoms contained in a
molecule of glucose or its metabolites are used to produce ATP.
During this vital process, which involves the electron transport
chain in mitochondria, reactive oxygen species (ROS) are
normally produced [1]. These molecules are highly reactive and
can cause cell membrane [2] and DNA damage [3], leading to cell
death if they are not adequately removed.
The brain consumes 20% of total body oxygen and utilizes 25%
of total body glucose, and hence this organ produces large
amounts of ROS [For a review on brain metabolism see 4].
Consequently, antioxidant defenses are of primary importance to
avoid oxidative stress and thus maintain normal brain functions.
Among the endogenous antioxidant defense mechanisms the GSH
system is the major cellular antioxidant and redox regulator in the
brain and its presence is fundamental for the protection against
oxidative stress induced by ROS and other oxidising molecules
[5–8].
The GSH redox system and glucose metabolism are clearly
linked, with GSH being necessary for the removal of the by-
products of glucose utilization for energy production. Further-
more, the pentose phosphate pathway (PPP), a pathway through
which glucose can be metabolized, is a major source of NADPH, a
cofactor necessary for the recycling of the oxidised GSH (GSSG)
[7]. During oxidative stress, the restoration of the initial high ratio
of GSH to GSSG depends on the synthesis of NADPH by glucose-
6-phosphate dehydrogenase (G6PD) [9–11], the first and rate-
limiting enzyme of the PPP, and on the presence of glucose
[12,13]. Indeed, if glucose levels are decreased or if G6PD is
inhibited, there is a subsequent reduction in NAPDH levels
leading to a decrease in the GSH/GSSG ratio, ultimately resulting
in oxidative stress and potentially in apoptosis [14]. However, to
our knowledge, the opposite effect, i.e. the impact of a deficit in
GSH on glucose utilization, has never been reported. Considering
that glucose metabolism leads to the production of ROS, we
hypothesize that an organism presenting with chronically low
GSH levels is likely to show adaptations regarding its energy use.
GSH deficits have been observed in several neurodegenerative and
psychiatric disorders including Alzheimer’s, Parkinson’s or Hun-
tington’s diseases [For reviews see 15,16] as well as in
schizophrenia [17–19]. In particular, a polymorphism in the gene
of the modulatory subunit of glutamate cysteine ligase (GCL), the
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schizophrenia [20]. Understanding the consequences of such a
deficit in these clinical conditions is essential to better focus
potential therapies.
Astrocytes are fundamental to both antioxidant defense and
energy metabolism in the brain [21]. Indeed, GSH levels are
higher in astrocytes than in neurons and increasing GSH in
astrocytes protects neurons against oxidative stress [22,23].
Astrocytes also represent the prevalent site of glucose entry into
the brain and they have the capacity to sense synaptic activity and
dynamically couple it to substrate distribution to neurons [24–26].
Indeed, extracellular lactate released by astrocytes following
glucose metabolism can be subsequently used by neurons to meet
their energy needs [27,28]. Furthermore, glycogen, which
represents the major form of glucose storage, is almost exclusively
found in astrocytes in the adult brain. Glycogen metabolism is
under the control of a restricted number of neurotransmitters and
modulators [29–35]. Experiments indicate that glycogen mobili-
zation can support neuronal viability in case of energy depletion
[36,37], and it is also implicated in normal brain function. For
instance, astrocytic glycogenolysis is increased during early
memory consolidation in the chicken brain [38,39], action
potential propagation in the mouse optic nerve to support the
energy needs of axons [40,41] and following sensory stimulation
[42]. It has also been demonstrated that the presence of glycogen is
essential for proper glutamatergic neurotransmission, i.e. vesicular
release and subsequent uptake [43]. Recent results indicate that
glycogen mobilization and the associated increase in lactate release
by astrocytes is required for the establishment of long-term
memory [44].
GSH is synthesized following two reactions catalysed by GCL
and GSH synthetase (GSS). GCL is a heterodimer made of a
catalytic subunit (GCLC), which contains the substrate’s binding
sites, and a modulatory subunit (GCLM). The latter modulates the
affinity of GCLC for substrates and inhibitors [45–47]. The gclm
knockout (KO) mouse represents a good model to study a chronic
GSH deficit [48,49], since it shows decrease in GSH levels of at
least 80% in liver, lung, pancreas and blood [50], as well as in
astrocytes [51]. Given the interplay between the glucose and GSH
metabolic pathways, the aim of the present study was to investigate
glucose metabolism and the response to oxidative stress in cultured
astrocytes from the GCLM-KO and wild-type (WT) mice. Our
results show that glycogen status and utilization are clearly
modified in astrocytes from GCLM-KO mice, and these
observations could be relevant to neuroenergetics impairments
in schizophrenia.
Materials and Methods
Ethics Statement
All experiments were performed in accordance with the
guidelines outlined in the Guide for the Care and Use of Laboratory
Animals (Swiss National Research Council). Approval #2091 was
given on March 13
th 2008 by the local Veterinary Office (Service
de la Consommation et des Affaires Veterinaires, Vaud canton,
Switzerland) for studying the effects of a deficit in glutathione in
cultured astrocytes from GCLM-KO mice and their correspond-
ing WT.
Materials
GCLM-KO mice, backcrossed with C57BL/6J mice over more
than 10 generations, were kindly provided by Timothy P. Dalton
and Ying Chen (Center for Environmental Genetics, Cincinnati,
OH, USA) [50], and were bred in our animal facility.
Unless otherwise stated, all chemicals were provided by Sigma-
Aldrich (St-Louis, MO, USA).
Primary cultures of cortical astrocytes
Astrocytes cultures from P1-2 C57BL/6 WT and GCLM-KO
mice were prepared as previously described [52,53]. Cortices were
dissected in DMEM medium (Invitrogen, Carlsbad, CA, USA)
containing 25 mM glucose and supplemented with 10% foetal calf
serum (BioConcept, Allschwil, Switzerland) and penicillin (100 u/
ml)/streptomycin (100 mg/ml). Cortical cells were mechanically
dissociated through needles with decreasing diameters and
resuspended in the supplemented DMEM medium. Astrocytes
were plated on 35-mm poly-L-ornithine-coated dishes and left to
grow for two weeks at 37uC in a humidified 5% CO2 atmosphere.
Under these conditions, more than 95% of the cells were
immunoreactive to glial fibrillary acidic protein (GFAP, astroglial
marker) [54]. Twice a week old medium was replace by 2.5 ml of
fresh medium. Under these conditions, the purity of the astrocytes
cultures is higher than 95% [54].
Experimental design
Twenty-four hours before any treatment or measurement, the
culture medium was removed and astrocytes were incubated in
2 ml of glucose-free DMEM supplemented with 5 mM glucose,
44 mM NaHCO3, 4 mM L-glutamine and 10 ml/l of penicillin-
streptomycin solution (DMEM5). In a first set of experiments, the
baseline metabolic status of WT and KO astrocytes was assessed
by measuring the rate of 2-deoxy-D-glucose (2DG) uptake and
glycogen levels. These measurements were also done in the
presence of 1,4-dideoxy-1,4-imino-d-arabinitol (DAB), an inhibitor
of glycogen phosphorylase [55] that was added to the medium for
1 hour. Lactate released from the cells and CO2 produced through
the PPP and the tricarboxylic acid (TCA) cycles were also
measured. In a second series of experiments, oxidative stress was
induced in both WT and KO astrocytes by adding tert-
Butylhydroperoxide (tBH; 10 mM and 50 mM) to the medium
for 40 minutes. tBH is a ROS-generating agent that was shown to
rapidly engage the GSH redox system [56]. Following this short
oxidative challenge, GSH and GSSG levels, 2DG uptake and
glycogen mobilization were measured. The metabolic response of
cells to the oxidative stress was also measured in the presence of
DAB, which was added to the medium 1 hour before and
maintained during tBH treatment. At the end of every treatment,
cell death was evaluated by measuring the activity of lactate
dehydrogenase (LDH) released into the medium by dying cells.
Glycogen assay
After appropriate treatment, cells were washed three times with
ice-cold PBS and sonicated in 30 mM HCl. The suspension was
used to measure glycogen as previously described [53]. In a first
100-ml aliquot, 300 ml of sodium-acetate buffer (0.1 M, pH 4.6)
was added. In a second aliquot, 300 ml of the same buffer
containing 1% (v/v) of amyloglucosidase (10 mg/ml; Roche
Diagnostics, Rothkreuz, Switzerland) was added. Aliquots were
incubated at room temperature (RT) for 30 min. Then, 2 ml of
Tris-HCl buffer (0.1 M; pH 8.1; 3.3 mM MgCl2, 0.2 mM ATP,
30 mM NADP, containing 0.7 U/ml of hexokinase and 0.35 U/
ml of glucose 6-phosphate dehydrogenase (HK-G6PD; Roche
Diagnostics) were added, and the mixture was incubated at RT for
30 min. Fluorescence associated with the NADPH formed was
then read on a fluorometer (excitation: 340 nm; emission: 450 nm)
after calibration with an appropriate standard curve using glucose
as standard. The first aliquot gives the sum of glucose and glucose
6-phosphate, and the second gives the sum of glycogen, glucose
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the subtracting the two results. A third aliquot (20 ml) was used to
measure the protein content using the Advance Protein Assay
(APA; Cytoskeleton, Denver, CO, USA). Results are presented in
nmol glycogen per mg of protein, one mole of glycogen
corresponding to one mole of glycosyl units originating from
glycogen.
2DG uptake assay
Glucose utilization was determined as previously described [53].
20 min before the end of the treatments, the medium was replaced
by 2 ml of DMEM5 medium containing 2-[1,2
3H] deoxy-D-
glucose ([
3H]2DG; 30–60 Ci/mmol; Anawa, Wangen, Switzer-
land) at a concentration of 1 mCi/ml. Substances were maintained
in the medium during this period. To stop the reaction the
medium was removed (and collected on ice for lactate release
assay, see below), cells were rinsed three times with ice-cold PBS,
and 2 ml of 10 mM NaOH/0.1% Triton X-100 was added to lyse
the cells. 500-ml aliquots were assayed for radioactivity by liquid
scintillation counting (Ecoscint XR, National Diagnostics, Atlanta,
GA, USA), and a 20-ml aliquot was used for measurement of
protein content using the APA. Results, which represent glucose
transporters-mediated uptake and subsequent phosphorylation,
were calculated by subtracting from total counts the portion that
was not inhibited by the glucose transporters inhibitor cytochalasin
B (25 mM). [
3H]2DG uptake, therefore glucose utilization, is
expressed in fmol per mg of protein.
Lactate release assay
Lactate release into the medium was measured enzymatically as
previously described [53]. To a 200-ml aliquot of the culture
medium (collected during the [
3H]2DG assay, see above), 1 ml of
a glycine-semicarbazide buffer (0.2 M; pH 10; NAD 3 mM, LDH
14 U/ml; Roche Diagnostics) was added. Samples were incubated
at 40uC for 1 h. After samples cooled down to RT, fluorescence
associated with the NADH formed was read on a fluorometer
(excitation: 340 nm; emission: 450 nm), after calibrating the
apparatus with a standard curve using sodium L-lactate as
standard. Lactate released into the medium is expressed in nmol
per mg of protein.
14CO2 production assay
Production of
14CO2 from D-[1-
14C]-glucose and D-[6-
14C]-
glucose (specific activities, 50–62 mCi/mmol; GE Healthcare,
Otelfingen, Switzerland) was used to determine glucose utilization
via the PPP and the TCA cycle, according to published procedure
[53]. Culture medium was removed and cells were incubated for
two hours in serum-free DMEM containing 2.5 mM glucose,
7.5 mM NaHCO3, 5 mM HEPES and penicillin-streptomycin
10 ml/l solution at 37uC in an atmosphere containing 5% CO2.
At the end of this incubation period, the medium was replaced by
2 ml of the same medium containing 2.3 mCi/ml D-[1-
14C]-
glucose, or D-[6-
14C]-glucose and culture dishes were placed in
sealed glass containers and incubated for 2 hours at 37uC. The
reaction was stopped by addition of 500 ml of 0.2 M HCl to the
cells and 1 ml Carbo-Sorb (PerkinElmer; Schwerzenbach, Swit-
zerland) on the bottom of the container. After a 1-hour
equilibration, containers were opened and two 400-ml aliquots of
Carbo-Sorb were assayed for radioactivity by liquid scintillation
counting. Production of
14CO2 from D-[1-
14C]-glucose reflects the
total CO2 produced in both PPP and TCA whereas
14CO2
produced from D-[6-
14C]-glucose reflects CO2 production in the
TCA only. CO2 production in the PPP is obtained by subtraction.
Total CO2 production from glucose can be calculated from the
molar ratio between unlabelled and labelled glucose. Cell protein
content was determined using the BCA protein assay reagent kit
(Pierce, Rockford, IL, USA) in parallel on cells from the same
culture and results are expressed as nmol of CO2 produced per
minute per mg of protein.
Gene expression
Astrocytes were harvested with trypsin-EDTA. RNA was
extracted with the Perfect Pure RNA cultured Cell Kit following
manufacturer’s instructions (5 Prime GmbH, Hamburg, Ger-
many). The concentration of each sample was measured with a
NanoDrop (NanoDrop Technologies, Wilington, DE, USA), and
the purity was assessed using the ratios of optic density at 260/
280 nm and 260/230 nm. The first strand of cDNA was
synthesized from 200 ng of total RNA using TaqMan H RT-
reagents (Applied Biosystem, Foster City, USA) after incubation
during 45 min at 48uC, followed by 5 min at 95uC and finally
stored at 4uC.
Three glycogen-related genes were amplified, i.e. the protein
targeting to glycogen (PTG), muscle glycogen synthase (GS) and
brain glycogen phosphorylase (GPhos). Cyclophylin was used as a
normalization gene. It is worth noting that the muscle GS is used
because it is the most common form of the enzyme found in the
brain [57]. Primer sequences (Table 1) were designed using primer
Express 3.0 software (Applied Biosystems) and oligonucleotides
were synthesized by Microsynth (Balgach, Switzerland). Quanti-
tative PCR was performed in an ABI Prism 7900 (Applied
Biosystems). The PCR mix was composed of 1.75 ml of RT-
products, 1.05 ml of forward and reverse primers (100 mM) and
17 ml of Sybr-Green PCR MasterMix (Applied Biosystem). Data
were computed using the sequence detector software SDS 2.3
(Applied Biosystems). To determine the level of expression of the
different genes, a macro (ExcelTM software) produced by the
genomic platform of the Geneva University (Frontiers in Genetics,
UNIGE, Geneva, Switzerland) was used. Results are expressed as
the expression levels of a given gene relative to the expression
levels of cyclophylin.
Determination of oxidized and reduced GSH
Quantification of total GSH and oxidized GSH (GSSG) was
performed with an assay based on the Tietze method [58] and
modified as described [59]. Cells were washed, scraped out of the
dish and sonicated before an aliquot was reserved for subsequent
analysis of protein content using the APA. Proteins in the
remaining cell solution were precipitated with 5-sulfosalicylic acid
and removed by centrifugation. The pH of the supernatant was
adjusted with triethanolamine. For GSSG measurement, an
aliquot of the supernatant was incubated for 45 to 60 min at
room temperature with 2-vinylpyridine, which forms a stable
complex with reduced GSH [60]. Sample aliquots were mixed
with a buffer containing 0.25 U/ml GSH reductase from baker’s
yeast, 0.25 mM EDTA, 0.075 mM 5,59-dithiobis(2-nitro-benzoic
acid) (DTNB) and 0.075 mM NADPH. The rate of increase in
absorbance at 405 nm, which measures the reduction of DNTB by
GSH, was proportional to the total GSH or to the amount of
GSSG when 2-VP was added. Total GSH content in cells are
expressed in nmol GSH/mg protein. GSSG levels are presented as
a percentage relative to reduced GSH (reduced GSH levels=total
GSH levels - 26GSSG levels).
Assessment of cell viability
Cell viability was assessed by measuring the activity of LDH
released in the culture medium by dying cells [Adapted from 61].
The decrease in NADH in the presence of pyruvate is proportional
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absorbance at 340 nm. The amount of LDH in the medium after
each treatment was reported to the total amount of LDH released
from cells after a freeze-thaw cycle. Results are presented as the
percentage of cell death relative to total cell death.
Statistical analyses
Statistical analyses were performed using the SPSS software.
Normal distribution of data was verified with the Shapiro-Wilk
test. Comparisons between WT and KO were done using the t-test
for independent samples when the normal distribution of data and
equality of variance criteria were fulfilled; otherwise, the non-
parametric Mann-Whitney test was used. The effect of treatments
was assessed with a one-way ANOVA with Treatment as group
factor, or a two-way ANOVA with DAB and Treatment as
between factors, followed by the Bonferroni’s post hoc multiple
comparison. For all statistical tests, significant probability level was
set to p#0.05 and data were presented as the mean 6 SEM.
Results
Characterization of glucose and glycogen metabolism in
WT and GCLM-KO astrocytes
Figures 1A and B show that there was no difference in the rate of
glucose utilization, as assessed by the [
3H]2DG uptake, and the
release of lactate into the medium between WT and KO astrocytes.
In order to reveal any changes in glucose metabolism through the
PPP or TCA cycles, CO2 production by both pathways was
determined. Fig. 1C shows that there was no difference between
WT and KO cells in the PPP/TCA ratios. In addition, when
looking at the amount of CO2 formed via each of these pathways,
results show that there is no significant difference between WT and
KO astrocytes. Indeed, CO2 production through the PPP is
0.07360.006 nmol/mg prot/min in WT and 0.08160.013 nmol/
mgprot/mininKO,and CO2 productionthroughthe TCA cycleis
0.03960.003 nmol/mg prot/min in WT and 0.03860.005 nmol/
mg prot/min in KO. On the other hand, glycogen levels were
significantly lower in KO cells (234.4%; p=0.009; Fig. 1D).
Low glycogen levels, as observed in KO (Fig. 1D), could be
indicative of a change in turnover. To test this hypothesis, a 24-h
treatment with 500 mM DAB, a selective inhibitor of GPhos, was
applied. Glycogen levels were significantly increased in KO (1.4-
fold increase; p=0.004), while no change was observed in WT
(Fig. 2). These results demonstrate that, at baseline, glycogen
turnover seems higher in the KO astrocytes than in WT cells. We
then aimed to determine if such an increase in glycogen turnover
was accompanied by modifications in the expression of genes
involved in astrocyte glycogen metabolism [62,63]. Figure 3 shows
that the relative gene expression levels of PTG, GS and GPhos are
lower in KO as compared to WT (279.9%, p,0.001; 226.1%,
p,0.001; 218.3%, p=0.003, respectively). Therefore, in spite of
lower amounts of these synthesizing and phosphorylating enzymes,
a higher glycogen turnover appears to be observed in KO
suggesting an increase in the activity of these enzymes.
Induction of an oxidative stress
More subtle differences between WT and GCLM-KO can be
revealed followingoxidative stress[64].Astrocytes were treatedwith
low concentrations of tBH (10 mMa n d5 0mM) for 40 minutes to
induce an oxidative challenge without increasing cell death. As
previously observed [51], prior to treatment, the GSH levels were
much lower in the KO compared to the WT (281.6%; p,0.001;
Fig. 4A), while the percentage of GSSG relative to GSH was not
significantly different (Fig. 4B). After 40-min treatments with 10 mM
and 50 mM tBH, there was no significant effect on both GSH and
GSSG levels in WT astrocytes (Fig. 4A and Fig. 4B). In contrast,
treatment with either 10 mMo r5 0mM tBH led to a decrease in
GSH levels in the KO cells (244.1%, p=0.004 and 267.9%,
p,0.001, respectively; Fig. 4A). Furthermore, treating KO
astrocytes with 50 mM tBH induced an increase the amount of
GSSG relative to GSH (3.5-fold increase; p=0.03; Fig. 4B).
It is important to note that assessment of cell death by measuring
LDH release in the medium showed no difference between WT and
KO (data not shown). Furthermore, a two-way ANOVA showed no
significant increase in LDH release after treatments with DAB,
10 mM tBH and 50 mM tBH (data not shown).
Differential use of glycogen and glucose following
oxidative stress
Under basal conditions, i.e. when no DAB and no stress are
applied, the rate of glucose utilization was similar between WT and
KO, while glycogen levels were lower in the KO astrocytes (Fig. 1,
see above and Fig. 5). Following an oxidative challenge with 10 mM
or 50 mM tBH, but in the absence of DAB, no significant change
was noticeable in the uptake of glucose in both WT (Fig. 5A) and
KO (Fig. 5B). In contrast to glucose utilization, a highly significant
effect of treatment on glycogen levels could be observed. Indeed, in
WT astrocytes, glycogen levels were significantly decreased after
Table 1. Nomenclature name, GeneBank Accession number and sequences of genes used in the quantification analyses.
Genes GeneBan
(nomenclature name) Accession Sequences
Number
Cyclophyline NM 008907 Forward: 59-CAAATGCTGGACCAAACACAA-
(Ppia) Reverse: 39-TCTGACTTACCGACCTACCG-
PTG NM 016854 Forward: 59-TGCCTCTCGGTCCAATGAG-
(Ppp1r3c) Reverse: 39-AACTGTTCAAGGCAGTACGG-
GSynt NM 030678 Forward: 59 GCTGGACAAGGAGGACTTCACT-
(Gys1) Reverse: 39-CAGAAAGGGTGGTCACACGT-
GPhos NM 153781 Forward: 59-GCTGCTCAACTGCCTACACATT-
(Pygb) Reverse: 39-GGAAACACGGGTCCTGACAA-
doi:10.1371/journal.pone.0022875.t001
GSH Deficit Affects Glycogen Metabolism
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22875treatment with 10 mM tBH compared to control (231.8%;
p=0.032). The decrease was even larger after 50 mM tBH
(288.6%; p,0.001). As for glucose utilization, glycogen levels were
not affected by oxidative stress in KO astrocytes (Fig. 5D). To
exclude the possibility that KO astrocytes are unable to mobilize
glycogen, they were exposed to the well-established glycogenolytic
agentnoradrenaline[NA;65]for40 min.ResultspresentedinFig.6
demonstrate that NA induced a massive glycogen mobilization in
both WT and KO astrocytes (284.3% and 290.4% respectively,
p,0.001).
In order to determine if glucose uptake is affected when glycogen
mobilization is impaired, cells were treated with DAB under basal and
tBH-treated conditions. As expected, DAB prevented glycogen
mobilization following tBH treatment in both WT (Fig. 5C) and KO
astrocytes (Fig. 5D). In WT, prevention of glycogen mobilization is
associated with higher rates of glucose utilization during oxidative stress
(Fig. 5A). Indeed, the increase in glucose utilization was significant after
treatments with 10 mM tBH (1.5-fold increase; p=0.004) and 50 mM
tBH (1.6-fold increase; p=0.006) in the presence of DAB, compared to
oxidative stress induced in the absence of DAB. In KO astrocytes,
DAB induced a significant increase in glucose utilization (1.6-fold
increase; p=0.002) after treatment with 50 mM tBH although no
increase was seen in response to 10 mMt B H .
Discussion
The aim of the present study was to determine if a deficit in
GSH would have an impact on glucose metabolism in cultured
astrocytes. Our results show that there is no difference in basal
glucose utilization, lactate release, and TCA and PPP activities in
GCLM-KO astrocytes compared to WT astrocytes. However,
basal glycogen levels are lower in astrocytes from KO mice and
Figure 1. Baseline characterization of WT and GCLM-KO astrocytes. A- there was no significant difference between WT and KO astrocytes in
glucose utilization as assessed by measuring the [
3H]2DG uptake rate during 20 min; n=6 in WT and n=11 in KO. B- no significant difference was
observed between WT and KO astrocytes in the amount of lactate released from the cells into the medium during 20 min; n=9 in WT and n=8 in KO.
C- there was no significant difference between WT and KO astrocytes in their preference for glucose to go through the PPP or the TCA. This was
assessed by measuring the CO2 released from the two pathways over a 2-h period, and results are presented as the amount of CO2 released from the
PPP relative to the amount coming from the TCA. The mean of individual ratio is presented. n=6. D- glycogen levels were lower in KO compared to
WT astrocytes; n=9 in WT and n=8 in KO. ** p,0.01; n.s., non significant.
doi:10.1371/journal.pone.0022875.g001
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be disturbed in these cells.
Glycogen levels are lower in astrocytes from GCLM-KO
mice
Basal glycogen levels are lower in KO astrocytes and blocking
the breakdown of glycogen for 24 h with DAB revealed a higher
turnover in KO than in WT cells. This lower glycogen level and
higher glycogen turnover in KO astrocytes is accompanied by a
decrease in the expression of the genes coding for key enzymes
implicated in the synthesis and degradation of glycogen; namely,
PTG, GS and GPhos. PTG is a protein that interacts with GS and
GPhos, and sets glycogen metabolism to a synthetic mode [66,67].
The decrease in the expression of the genes coding for proteins
implicated in the synthesis and degradation of glycogen appears to
be related to the low levels of glycogen observed in GCLM-KO
mice. This observation is in line with results obtained from a study
using PTG heterozygous mice and showing decreased glycogen
stores in adipose tissue, liver, heart, and skeletal muscle in these
mice compared to WT mice [68]. However, to our knowledge, this
is the first demonstration that chronically low GSH levels and/or
oxidative stress could affect PTG gene expression. Despite the
clear involvement of PTG in glycogen metabolism, how its
function is regulated is not known [69].
In WT astrocytes, glycogen is mobilized following
oxidative challenge
Phenotypes related to a defect in the genes coding for the
enzymes required for GSH synthesis can be revealed under
Figure 2. Effect of DAB on glycogen levels in WT and GCLM-KO
astrocytes. In the presence of 500 mM DAB for 24 hours, glycogen
levels were increased in KO astrocytes, but not in WT. n=9, except for
KO with DAB where n=7. ** p,0.01.
doi:10.1371/journal.pone.0022875.g002
Figure 3. Basal expression of glycogen-related genes in WT
and GCLM-KO astrocytes. Expression was lower in KO compared to
WT astrocytes for all three genes studied. n=9. ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0022875.g003
Figure 4. Effect of tBH treatment in GSH and relative GSSG
levels in WT and GCLM-KO astrocytes. A- reduced GSH levels were
highly significantly lower in KO than in WT astrocytes and tBH
treatment led to a further decrease in GSH levels in KO astrocytes
without significantly affecting these levels in WT. B- percentage of GSSG
relative to reduced GSH were significantly increased compared to
control only after treatments with tBH 50 mM in GCLM-KO astrocytes.
n=9.1 p,0.05 vs no tBH; 11 p,0.01 vs no tBH; 111 p,0.001 vs no tBH;
*** p,0.001 vs other genotype.
doi:10.1371/journal.pone.0022875.g004
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therefore submitted to a treatment with tBH, a ROS-generating
agent. After 40 minutes of this treatment, GSH and GSSG levels
were maintained at normal values in WT astrocytes, showing that
the GSH used to detoxify the tBH had been regenerated through
the redox cycle. During GSH peroxidase-catalyzed reduction of
tBH, the ratio of GSH to GSSG is decreased and in order to re-
establish a normal ratio, GSSG must be reduced by GSH
reductase [56]. For this reaction to occur, production of the
reduced equivalent NADPH through the PPP is necessary [14].
Glucose 6-phosphate, which is used as the primary substrate for
PPP, can be obtained by the direct phosphorylation of glucose by
hexokinases or by degradation of glycogen and the subsequent
action of phosphoglucomutase. Rahman and collaborators [70]
have demonstrated that in astrocytes, glycogen is mobilized
following an oxidative insult. They proposed that NADPH
regeneration via PPP could, at least in part, be met by glycogen
mobilization. In line with these results, we observed that glucose
utilization was not changed in WT astrocytes following tBH
treatment, while there was a concentration-dependent increase in
glycogen mobilization. Such a metabolic response appears
important to detoxify oxidative compounds and to maintain
GSH levels during a short stress period such as the one used in the
present study. More massive and sustained oxidative stress may
Figure 5. Effect tBH and DAB on glucose utilization and glycogen mobilization in WT and GCLM-KO astrocytes. A- glucose utilization
was increase in WT astrocytes following a 40-min treatment with 10 mM and 50 mM tBH in the presence of DAB. n=6. B- glucose utilization was
increase in KO astrocytes following a 40-min treatment with 50 mM tBH in the presence of DAB. n=11–12. C- glycogen levels were not changed
following DAB treatment, but were highly significantly decreased following 40-min tBH treatment in WT astrocytes. n=9. D- glycogen levels were not
significantly affected by either DAB or tBH treatment in GCLM-KO astrocytes. n=6–9. 1 p,0.05 vs no tBH; 111 p,0.001 vs no tBH; ** p,0.01 vs other
genotype; *** p,0.001 vs other genotype; n.s., non significant.
doi:10.1371/journal.pone.0022875.g005
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cellular metabolism and viability [71].
In GCLM-KO astrocytes, glycogen mobilization is
unchanged following oxidative challenge
Unlike WT, KO astrocytes were unable to mobilize glycogen to
detoxify ROS. This observation is puzzling, particularly in view of
the fact that treatment with NA led to a near-complete depletion
of glycogen in both WT and KO. Therefore, the absence of an
effect of tBH on glycogen mobilization in KO astrocytes cannot be
attributed to the inability of these cells to mobilize glycogen. In
these cells, GSH levels were also significantly lower following tBH
treatment compared to the non-stress condition, indicating that
the GSH used to detoxify the ROS could not be regenerated. A
possible explanation for this observation is that since no increase in
the mobilization of glycogen occurred, it is likely that not enough
de novo NADPH was produced via the PPP. Following treatment
with 10 mM tBH, although GSH was oxidized in the tBH
detoxification process, no change in the redox ratio of GSH
(amount of GSSG in relation to GSH) was observed, indicating
that GSSG was probably released in the extracellular compart-
ment [72]. However, after treatment with 50 mM tBH, the ratio
GSSG/GSH was not maintained any longer indicating that cells
were under oxidative stress, although cell death was not
significantly increased as reflected by the levels of LDH released
in the medium. It has been shown that decreasing GSH levels in
cortical cultures causes the suppression of oxidative stress-induced
activation of the PPP [73]. This suggests, along with the
observation that glycogen is normally mobilized following
treatments with oxidative stressors [this study and 70], that a
metabolic coupling between oxidative stress, activation of PPP and
glycogen mobilization exists in astrocytes. This coupling may be
lost or impaired in GCLM KO cells. However, the lower levels of
basal glycogen in KO astrocytes and the fact that these cells do not
mobilize glycogen following an oxidative stress indicate that they
developed an alternative, and still not fully elucidated, defense
strategy such as the release of GSSG into the extracellular space
(see above), even if the implication of other defense strategies
cannot be excluded.
Differential effect of DAB in WT and GCLM-KO astrocytes
When DAB, an inhibitor of the breakdown of glycogen, was
present, glucose utilization was increased in WT following the
oxidative challenge with tBH. This observation indicates that in
the absence of glycogen as a source of energy, WT astrocytes were
able to compensate this deficiency by increasing their glucose
utilization, demonstrating the high plasticity of this cell type with
regard to energy metabolism. The situation in KO astrocytes is
quite different. Forty minutes after the treatment with 10 mM tBH,
the uptake of glucose in the presence of DAB was unchanged. In
these cells, DAB led to an increase in the uptake of glucose only
with 50 mM tBH, a concentration that induced oxidative stress but
no glycogen mobilization. Thus, in KO astrocytes a stimulatory
effect of DAB on glucose utilization is observed under conditions
for which no significant increase in glycogen mobilization takes
place when no DAB was applied. This is in is in contrast to what is
observed in WT astrocytes and such an apparent paradox can be
resolved when taking into account the different rates of glycogen
turnover in KO and WT astrocytes. Indeed, in WT astrocytes,
DAB produces its effect on glucose utilization by preventing
glycogen mobilization, whereas its effect on KO cells would rather
be linked to blockade of glycogen turnover. The metabolic
mechanisms by which glycogen turnover may become limiting in
KO astrocytes only following a major oxidative stress (50 mM
versus 10 mM tBH), and how an increase in glucose utilization
could compensate for this, are not known. However, they highlight
specific cellular adaptations of KO astrocytes with regards to
glycogen metabolism in general and to changes in glycogen
turnover in particular.
GSH deficit and neuroenergetics in schizophrenia
Results presented here demonstrate major differences in
relation to oxidative stress defense mechanisms between KO and
WT astrocytes. Knowing that the end result of glucose metabolism
is accompanied by the production of ROS, one can postulate that
cellular adaptation towards oxidative stress in KO cells may partly
involve a constraint/limitation of glucose utilization and glycogen
mobilization when an oxidative challenge is already monopolizing
the GSH system. Antioxidant defense system impairment and
redox dysregulation [For recent reviews, see 19,74,75], in
particular GSH deficit [17–19], have been well documented in
schizophrenia. In the frontal cortex of GSH deficit models,
morphological abnormalities, such as a decrease in dendritic spine
density is observed possibly reflecting an inability of astrocytes to
protect neurons from oxidative stress in this dopamine-rich region
[17,76]. The present study shows that both glucose uptake (under
stress condition) and glycogen metabolism are modified in
astrocytes from a chronically GSH-deficient mouse compared to
WT mice. In line with these results, altered glucose utilization is
observed in prefrontal and anterior cingulate cortices of
schizophrenia patients [77–80], and this decrease as been
associated with cognitive impairment [81].
Conclusion
Our main observation is that glycogen status and utilization are
clearly modified in astrocytes from GCLM-KO mice. WT
astrocytes show an increase in their glycogen mobilization, or
glucose utilization if glycogen is not available, following an
oxidative stress. However, KO astrocytes do not increase their
consumption of energy substrates unless an extreme oxidative
challenge occurs. This observation is likely to reflect an adaptation
of the GCLM-KO astrocytes directed at reducing the production
of ROS through the metabolism of glucose. More studies will be
necessary to find out which source of energy these cells turn to
when needed and what are the effects of such important
disturbances in the GCLM-KO astrocytes on their neighboring
neurons.
Figure 6. Effect NA treatment on glycogen mobilization in WT
and GCLM-KO astrocytes. NA significantly induced a massive
glycogen mobilization in both WT and KO astrocytes. n=9 in WT and
n=6–8 in KO. *** p,0.001.
doi:10.1371/journal.pone.0022875.g006
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